Geneos Therapeutics Raises $17M in Series A2 Funding
Summary
In conjunction with the financing, Dr. Ted Fjällman, Partner, Flerie Invest joined Geneos’ Board of Directors. The company intends to use the funds to expand the GT-30 Phase Ib/IIa clinical trial, its pipeline into a new indication, and continued operations. Geneos Therapeutics is a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies. The proprietary GT-EPIC™ Neoantigen-Targeting Platform is based on the design and delivery of highly optimized synthetic DNA plasmids and their combinations for cancer immunotherapy. The platform allows Geneos to develop personalized therapies tailored to each patient’s unique tumor mutations.
Funding
Review available funding amount, funding date, investors, and linked company information related to Geneos Therapeutics Raises $17M in Series A2 Funding in the interactive ISVWorld profile.